Evidence map›Paper›PMID 39333693›Full record

ArticleScientific reports2024

TBI/Cy followed by auto-HSCT is a good choice next to allo-HSCT for patients with T-LBL/ALL.

Jinghua Mao, Jurui Ge, Shiqi Ding, Zhenchang Sun, Feifei Nan, Hui Yu, Jiayin Ding, Xinyi Wang, Zhuling Liu, Mingzhi Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jinghua Mao *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jurui Ge *Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Shiqi Ding *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhenchang SunDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Feifei NanDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Hui YuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jiayin DingDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xinyi WangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhuling LiuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Mingzhi ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. mingzhi_zhang1@163.com.
Xiaorui FuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. zymfxr_2006@126.com.

Funding

The Key Scientific Research Project of Colleges and Universities in Henan Province 23A320028The Science and Technology Research Project of Henan Province 222102310696The Science and Technology Research Project of Henan Province 232102310274The Science and Technology Research Project of Henan Province 232102310451
6 · The paper itself

Abstract

The aim of this retrospective study was to evaluate the efficiency and safety of total body irradiation plus cyclophosphamide (TBI/Cy) followed by autogenetic hematopoietic stem cell transplantation (auto-HSCT) in T-LBL/ALL patients that cannot receive allogeneic hematopoietic stem cell transplant (allo-HSCT). Between 2013 and 2023, 24 patients received auto-HSCT following by TBI/Cy, 26 patients underwent allo-HSCT, all patients achieved completed hematopoietic reconstitution after HSCT. The progression free survival (PFS) and overall survival (OS) had no statistically significant differences between the two groups (P = 0.791, HR 1.127, 95%CI 0.456-2.785; P = 0.456, HR 0.685, 95%CI 0.256-1.828). Although the cumulative incidence of relapse was lower for patients who received allo-HSCT than auto-HSCT (P = 0.033, HR 3.707, 95%CI 1.188-11.570, 2-year relapse 11.5% vs. 33.3%), the incidence of non-relapse mortality (NRM) was higher than that in the auto-HSCT group (P = 0.014, HR 0.000, 95%CI -1.000 - -1.000, 2-year NRM, 23.1% vs. 0%). Trough Landmark analysis, the two groups showed a statistically significant difference in 3-year PFS and 4-year OS curves (Figure S2A&B, P = 0.039, HR 0.426, 95%CI 0.163-1.117; P = 0.014, HR 0.317, 95%CI 0.113-0.887). By COX analysis, poor baseline performance status (ECOG-PS ≥ 2) and CNS involvement were risk factors for PFS and OS. In conclusion, TBI/Cy followed by auto-HSCT is a good choice next to allo-HSCT for patients with T-LBL/ALL.

Indexed as

CyclophosphamideHematopoietic Stem Cell TransplantationWhole-Body IrradiationAdolescentAdultChildChild, PreschoolFemaleGraft vs Host DiseaseHumansMaleMiddle AgedRetrospective StudiesTransplantation, AutologousTransplantation ConditioningTransplantation, HomologousCyclophosphamideAllogeneic hematopoietic stem cell transplantationAutogeneic hematopoietic stem cell transplantationT-cell lymphoblastic lymphoma/LeukemiaTotal body irradiation

Identifiers

PMID39333693
PMCPMC11437004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.